PMID- 35330453
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220329
IS  - 2075-4426 (Print)
IS  - 2075-4426 (Electronic)
IS  - 2075-4426 (Linking)
VI  - 12
IP  - 3
DP  - 2022 Mar 13
TI  - Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor 
      Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.
LID - 10.3390/jpm12030454 [doi]
LID - 454
AB  - The available data suggest differences in the course of type 2 diabetes mellitus 
      (T2DM) between men and women, influenced by the distinguishing features of the 
      sex. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a relatively new 
      class of antidiabetic drugs that act by mimicking the function of endogenous 
      glucagon-like peptide 1. They constitute valuable agents for the management of 
      T2DM as, in addition to exerting a strong hypoglycemic action, they present 
      cardiorenal protective properties, promote weight loss, and have a good safety 
      profile, particularly with respect to the risk of hypoglycemia. Due to the 
      precedent of studies having identified sexual dimorphic elements regarding the 
      action of other antidiabetic agents, ongoing research has attempted to examine 
      whether this is also the case for GLP-1 RAs. Until now, sex differences have been 
      observed in the impact of GLP1-RAs on glycemic control, weight reduction, and 
      frequency of adverse events. On the contrary, the question of whether these drugs 
      differentially affect the two sexes with respect to cardiovascular risk and 
      incidence of major adverse cardiovascular events remains under investigation. 
      Knowledge of the potential sex-specific effects of these medications is extremely 
      useful for the implementation of individualized therapeutic plans in the 
      treatment of T2DM. This narrative review aims to present the available data 
      regarding the sex-specific action of GLP-1 RAs as well as to discuss the 
      potential pathophysiologic mechanisms explaining these dissimilarities.
FAU - Rentzeperi, Elpiniki
AU  - Rentzeperi E
AD  - Division of Endocrinology and Metabolism and Diabetes Center, First Department of 
      Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA 
      University Hospital, 54636 Thessaloniki, Greece.
FAU - Pegiou, Stavroula
AU  - Pegiou S
AD  - Division of Endocrinology and Metabolism and Diabetes Center, First Department of 
      Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA 
      University Hospital, 54636 Thessaloniki, Greece.
FAU - Koufakis, Theocharis
AU  - Koufakis T
AUID- ORCID: 0000-0002-5853-1352
AD  - Division of Endocrinology and Metabolism and Diabetes Center, First Department of 
      Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA 
      University Hospital, 54636 Thessaloniki, Greece.
FAU - Grammatiki, Maria
AU  - Grammatiki M
AD  - Division of Endocrinology and Metabolism and Diabetes Center, First Department of 
      Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA 
      University Hospital, 54636 Thessaloniki, Greece.
FAU - Kotsa, Kalliopi
AU  - Kotsa K
AUID- ORCID: 0000-0003-2376-740X
AD  - Division of Endocrinology and Metabolism and Diabetes Center, First Department of 
      Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA 
      University Hospital, 54636 Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220313
PL  - Switzerland
TA  - J Pers Med
JT  - Journal of personalized medicine
JID - 101602269
PMC - PMC8950819
OTO - NOTNLM
OT  - GLP-1 receptor agonists
OT  - diabetes
OT  - sex/gender differences
OT  - weight loss
COIS- T.K. has received honoraria as a speaker from AstraZeneca, Boehringer Ingelheim, 
      Pharmaserve Lilly and Novo Nordisk and has participated in sponsored studies by 
      Eli-Lilly. M.G. has participated in sponsored studies by Eli-Lilly. K.K. has 
      received honoraria for lectures/advisory boards and research support from Astra 
      Zeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi-Aventis, ELPEN, MSD, and 
      Novo Nordisk. E.R. and S.P. declare no conflict of interest.
EDAT- 2022/03/26 06:00
MHDA- 2022/03/26 06:01
PMCR- 2022/03/13
CRDT- 2022/03/25 01:13
PHST- 2021/11/30 00:00 [received]
PHST- 2022/03/02 00:00 [revised]
PHST- 2022/03/10 00:00 [accepted]
PHST- 2022/03/25 01:13 [entrez]
PHST- 2022/03/26 06:00 [pubmed]
PHST- 2022/03/26 06:01 [medline]
PHST- 2022/03/13 00:00 [pmc-release]
AID - jpm12030454 [pii]
AID - jpm-12-00454 [pii]
AID - 10.3390/jpm12030454 [doi]
PST - epublish
SO  - J Pers Med. 2022 Mar 13;12(3):454. doi: 10.3390/jpm12030454.